Elevated levels of PAX7 in breast cancer patients were linked to lower overall survival rates, while no notable prognostic correlation was found in glioma, lung adenocarcinoma, lung squamous cell carcinoma, or gastric adenocarcinoma. Here, PAX7 is linked to glioma.